Circulating cell-free nucleic acids as biomarkers in colorectal cancer screening and diagnosis
- PMID: 26652067
- DOI: 10.1586/14737159.2016.1132164
Circulating cell-free nucleic acids as biomarkers in colorectal cancer screening and diagnosis
Abstract
Screening methods for the most frequent diagnosed malignant tumor, colorectal cancer (CRC), have limitations. Circulating cell-free DNA (cfDNA) analysis came into focus as a potential screening test for CRC. Detection of epigenetic and genetic alterations of cfDNA as DNA methylation or DNA mutations and related ribonucleic acids may improve cancer detection based on unique, CRC-specific patterns. In this review the authors summarize the CRC-specific nucleic acid biomarkers measured in peripheral blood and their potential as screening markers. Detection of DNA mutation has inadequate sensitivity; however, methylated DNA can be established with higher sensitivity from CRC plasma samples. The ribonucleic acid based miRNA studies represented higher sensitivity for CRC as compared with mRNA studies. Recently, isolation of cfDNA has become automated, highly reproducible and a high throughput method. With automated possible diagnostic tools, a new approach may be available for CRC screening as liquid biopsy.
Keywords: Colorectal cancer; DNA genetic alterations; RNA expression alterations; circulating cell-free DNA; screening.
Similar articles
-
Circulating cell-free nucleic acids as biomarkers in colorectal cancer screening and diagnosis - an update.Expert Rev Mol Diagn. 2019 Jun;19(6):477-498. doi: 10.1080/14737159.2019.1613891. Epub 2019 May 21. Expert Rev Mol Diagn. 2019. PMID: 31046485 Review.
-
Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients.Int J Cancer. 2017 Apr 15;140(8):1888-1898. doi: 10.1002/ijc.30565. Epub 2017 Jan 5. Int J Cancer. 2017. PMID: 27943272
-
[Characteristics and diagnostic applications of circulating cell-free DNA in colorectal cancer].Orv Hetil. 2019 Jul;160(30):1167-1177. doi: 10.1556/650.2019.31486. Orv Hetil. 2019. PMID: 31327245 Review. Hungarian.
-
Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer.Acta Oncol. 2017 Jan;56(1):7-16. doi: 10.1080/0284186X.2016.1253861. Acta Oncol. 2017. PMID: 28010185 Review.
-
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer.Gut. 2018 Nov;67(11):1995-2005. doi: 10.1136/gutjnl-2016-313372. Epub 2017 Oct 5. Gut. 2018. PMID: 28982739 Free PMC article. Clinical Trial.
Cited by
-
Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay.Nanotheranostics. 2020 Aug 25;4(4):224-232. doi: 10.7150/ntno.48905. eCollection 2020. Nanotheranostics. 2020. PMID: 32923312 Free PMC article.
-
Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer.Transl Oncol. 2017 Aug;10(4):693-698. doi: 10.1016/j.tranon.2017.06.005. Epub 2017 Jul 7. Transl Oncol. 2017. PMID: 28692881 Free PMC article.
-
Clinical Implications and Future Perspectives of Circulating Tumor Cells and Biomarkers in Clinical Outcomes of Colorectal Cancer.Transl Oncol. 2016 Aug;9(4):340-7. doi: 10.1016/j.tranon.2016.06.006. Transl Oncol. 2016. PMID: 27567958 Free PMC article. Review.
-
Diagnostic value of long noncoding RNAs for hepatocellular carcinoma: A PRISMA-compliant meta-analysis.Medicine (Baltimore). 2017 Jul;96(28):e7496. doi: 10.1097/MD.0000000000007496. Medicine (Baltimore). 2017. PMID: 28700498 Free PMC article. Review.
-
Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine.Ann Oncol. 2017 Mar 1;28(3):468-477. doi: 10.1093/annonc/mdw619. Ann Oncol. 2017. PMID: 27998963 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical